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in the Azi group (12%, 26 of 224) compared to the Clari
group (6%, 14 of 221). The total drug costs for additional
antibiotics were $853 and $690 for the Azi and Clari
groups, respectively. The major reason for additional anti-
biotics was due to bacteriological and clinical failures.
CONCLUSIONS: Clari is superior to Azi in the eradica-
tion of S. pyogenes and in the resolution of symptoms of
pharyngitis/tonsillitis. In addition, more subjects in the
Azi group had additional antibiotics prescribed for phar-
yngitis/tonsillitis during the follow-up period. The lower
rate of additional antibiotic usage would be expected to
result in cost savings in the overall management of phar-
yngitis/tonsillitis.
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OBJECTIVE: To supplement previous efficacy analyses
from pivotal Phase III trials with a comparison of the
community-acquired pneumonia (CAP)-related costs of
inpatient treatment using either IV levofloxacin or IV
ceftriaxone as initial primary therapy.
METHODS: Patients with a primary diagnosis of CAP
were enrolled in a prospective, randomized, open-label, ac-
tive-controlled Phase III clinical trial. They were assigned
to one of two treatment groups: levofloxacin (IV or PO)
and ceftriaxone (IV) and/or cefuroxime axetil (PO) in in-
patient and outpatient settings. Resource utilization data
were collected alongside clinical trial data. To make legiti-
mate and meaningful cost comparisons between similar
types of patients (inpatients) getting similar (IV) drugs, this
economic analysis examined only the resource utilization
of inpatient trial enrollees who received IV formulations as
initial treatment. Medicare resource cost estimates were
multiplied by resource units used by patients to generate
cost estimates. Sample size had been determined based on
efficacy endpoints in the Phase III trial protocol.
RESULTS: The results showed a statistically significant
total cost difference per patient that favored levofloxacin
over ceftriaxone ($6012 versus $7422; a difference of
$1410; p  0.048). Levofloxacin was also associated
with a statistically significant reduction in mean study
medication cost per patient ($195 versus $388; a differ-
ence of $193; p  0.0001).
CONCLUSIONS: As initial primary inpatient treatment
of adults with community-acquired pneumonia, IV levof-
loxacin is less costly than IV ceftriaxone, the most pre-
scribed inpatient CAP treatment.
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OBJECTIVES: The study purpose was to determine
whether a disease management program (DSM) using
dyspepsia guidelines would improve provider compliance
with “best practices” and result in improved health and/
or economic outcomes.
METHODS: We randomized eight clinics in a capitated
managed care medical group to “usual care” versus a dys-
pepsia DSM for non-NSAID and NSAID-related dyspep-
sia. This analysis includes only patients with non-NSAID-
related dyspepsia. The program included the use of evi-
dence-based practice guidelines, “on-site” HP testing, aca-
demic detailing of physicians, and patient education.
Symptom severity, and quality of life were measured at
baseline, 3 and 6 months, and compliance with guidelines
and utilization was assessed at 6 months.
RESULTS: One hundred sixty-seven intervention and 180
control patients entered the final analysis. There were no
significant differences in baseline characteristics in the two
groups. HP testing was performed in 61% of intervention
and 11% of control patients (P  0.001). Appropriate
anti-HP therapy was given to 100% of HP-positive inter-
vention patients and 0% of HP-positive control patients
(P  0.001). Drug costs were reduced by $4.70 PMPM in
the intervention group compared to the control group (P 
0.001). Other than a reduction in costs attributable to
barium radiography in the intervention group (P  0.05),
there were no significant differences between groups in
the costs attributable to non-drug resource utilization.
Symptom severity and quality of life scores were similar
between groups at 3 and 6 months.
CONCLUSIONS: This preliminary analysis suggests that
a DSM using evidence-based guidelines and academic de-
tailing improved the process of care for patients with dys-
pepsia not taking NSAIDs. Implementation of this DSM
resulted in significant reductions in PMPM pharmacy
costs, without compromising symptom severity or health-
related quality of life.
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